



Chalk River National Research Universal reactor

<https://policybase.cma.ca/en/permalink/policy9919>

Policy Type: Policy resolution
Last Reviewed: 2017-Mar-04
Date: 2010-Aug-25
Topics: Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution: GC10-102

The Canadian Medical Association urges the federal government to make a public commitment to keep the Chalk River National Research Universal reactor operational for as long as necessary beyond the announced date of 2016 and until secure alternative supplies of isotopes or alternative radiopharmaceuticals are proven and available.



Essential drugs for the exclusive use of developing countries

<https://policybase.cma.ca/en/permalink/policy415>

Policy Type: Policy resolution
Last Reviewed: 2014-Mar-01
Date: 2000-Aug-16
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
Resolution: GC00-221

The CMA calls on governments and pharmaceutical manufacturers in Canada to ensure a supply of essential drugs for the exclusive use of developing countries, and to offset the numerous barriers hindering access to these drugs.



Non-medicinal ingredients in drug products

<https://policybase.cma.ca/en/permalink/policy802>

Policy Type: Policy resolution
Last Reviewed: 2017-Mar-04
Date: 1985-Aug-25
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution: GC85-28

The Canadian Medical Association calls on Health Canada to facilitate the dissemination of information to health professionals and consumers concerning the presence, in drug products, of non-medicinal ingredients that can cause adverse reactions.